- Home
- EXAI vs SIGA Comparison
EXAI vs SIGA Comparison
Compare EXAI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAI
- SIGA
- Stock Information
- Founded
- EXAI 2012
- SIGA 1995
- Country
- EXAI United Kingdom
- SIGA United States
- Employees
- EXAI N/A
- SIGA N/A
- Industry
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- EXAI Health Care
- SIGA Health Care
- Exchange
- EXAI Nasdaq
- SIGA Nasdaq
- Market Cap
- EXAI 635.8M
- SIGA 551.0M
- IPO Year
- EXAI 2021
- SIGA 1997
- Fundamental
- Price
- EXAI $5.28
- SIGA $7.63
- Analyst Decision
- EXAI Hold
- SIGA
- Analyst Count
- EXAI 4
- SIGA 0
- Target Price
- EXAI $7.00
- SIGA N/A
- AVG Volume (30 Days)
- EXAI 485.2K
- SIGA 422.0K
- Earning Date
- EXAI 11-15-2024
- SIGA 11-07-2024
- Dividend Yield
- EXAI N/A
- SIGA 7.83%
- EPS Growth
- EXAI N/A
- SIGA 197.35
- EPS
- EXAI N/A
- SIGA 1.17
- Revenue
- EXAI $26,566,153.00
- SIGA $172,956,776.00
- Revenue This Year
- EXAI $156.33
- SIGA $16.98
- Revenue Next Year
- EXAI N/A
- SIGA $16.49
- P/E Ratio
- EXAI N/A
- SIGA $6.56
- Revenue Growth
- EXAI N/A
- SIGA 76.90
- 52 Week Low
- EXAI $3.80
- SIGA $4.26
- 52 Week High
- EXAI $7.91
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- EXAI 57.06
- SIGA 59.91
- Support Level
- EXAI $4.80
- SIGA $6.80
- Resistance Level
- EXAI $5.26
- SIGA $7.51
- Average True Range (ATR)
- EXAI 0.23
- SIGA 0.36
- MACD
- EXAI 0.03
- SIGA 0.13
- Stochastic Oscillator
- EXAI 81.16
- SIGA 76.87
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.